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Introduction: Multisystem manifestations of myotonic dystrophies type 1 (DM1) and 2 (DM2)
are well known. Peripheral nerve involvement has been reported in DM1 but not in genetically
conﬁrmed DM2. The aim of our study was to assess peripheral nerve involvement in DM2
using nerve conduction studies and to compare these results with ﬁndings in DM1.
Methods: We prospectively studied patients with genetically conﬁrmed DM2 (n = 30) and
DM1 (n = 32). All patients underwent detailed neurological examination and nerve conduc-
tion studies.
Results: Abnormalities in electrophysiological studies were found in 26.67% of patients with
DM2 and in 28.13% of patients with DM1 but the criteria of polyneuropathy were fulﬁlled in
only 13.33% of patients with DM2 and 12.5% of patients with DM1. The polyneuropathy was
subclinical, and no correlation was found between its presence and patient age or disease
duration.
Conclusions: Peripheral nerves are quite frequently involved in DM2, but abnormalities
meeting the criteria of polyneuropathy are rarely found. The incidence of peripheral nerve
involvement is similar in both types of myotonic dystrophy.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Muscular dystrophies are inherited, progressive, degenerative
disorders of skeletal muscles. Myotonic dystrophies (DM) are* Corresponding author at: Department of Neurology, Medical Univers
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0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Scharacterized by two important additional features: myotonia
(the phenomenon which can be seen clinically and electro-
physiologically) and extramuscular multisystem involvement.
Both these features can lead to large variability of the clinical
presentation. Two different types of myotonic dystrophies,ity of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
p. z o.o. All rights reserved.
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previously termed proximal myotonic myopathy, PROMM), are
currently distinguished. Although DM1 and DM2 are similar in
terms of extramuscular system involvement, there are also
some clinical differences which help to distinguish them from
each other, most importantly age at the onset of the disease,
the pattern of muscle weakness, absence of congenital and
childhood-onset forms of DM2, and limited evidence of central
nervous system (CNS) involvement in DM 2 [1,2].
Myotonic dystrophy type 2 (DM2) is an autosomal dominant
disorder caused by an expansion of the CCTG repeat in the ﬁrst
intron in the ZNF 9 gene encoding zinc ﬁnger protein 9 [3]. DM2
is a multisystem disorder characterized by myotonia and
muscle weakness. The weakness typically affects proximal
muscles, in contrast to DM1 which initially affects distal upper
limb muscles. The onset of weakness is relatively late, most
often in the fourth or ﬁfth decade of life [4]. DM2 is also a
clinically milder disease that DM1, with fewer patients
requiring assistive devices [5], no cases of respiratory failure
reported to date [1] and almost normal life expectancy [4]. Most
patients complain of muscle pain which seems to be
independent of the severity of myotonia and exercise
intensity, and may be the most disabling symptom [6]. Other
characteristic signs and symptoms of DM2 are general fatigue
and calf hypertrophy [2,5]. Extramuscular clinical features
include cardiac conduction defects, cataract, endocrine
changes including testicular failure and diabetes mellitus
[4–6], and cognitive symptoms such as problems with
organization, concentration and word ﬁnding which are
considerably milder then in DM1 [5–7]. DM2 patients are also
generally spared from complications of general anesthesia
[2,4]. To the best of our knowledge, the peripheral nervous
system involvement has not been reported until now in
genetically conﬁrmed DM2.
Myotonic dystrophy type 1 (DM1) is also an autosomal
dominant disease caused by an unstable CTG repeat expan-
sion in the 30 untranslated region of the myotonic dystrophy
protein kinase (DMPK) gene on chromosome 19q13.3 [8]. It is
the most common muscular dystrophy in adult life, presenting
with a wide spectrum of extramuscular symptoms,
e.g. cataract, frontal balding, cardiac conduction abnormali-
ties, testicular atrophy with associated reduced fertility,
diabetes mellitus, and irritable bowel-like symptoms
[1,2,5,6,9–11]. There is also evidence for CNS involvement
with cognitive impairment/mental retardation, psychological
dysfunction or excessive daytime sleepiness [1,2,5,12]. The
issue of peripheral nerve involvement in DM1 is still a matter
of debate. Although patients seldom complain of sensory
symptoms, some authors described peripheral neuropathy
[13–18] or abnormal results of peripheral nerve conduction
studies [19–22] in patients with DM1. Other reports, however,
indicate no primary peripheral nervous system involvement in
DM1 [23–26]. Some experimental studies in animal models of
DM1 suggested that peripheral motor neuropathy can be
linked to a large CTG expansion and a more severe form of DM1
[27]. This is consistent with previous reports showing an
increasing severity of neuromuscular involvement in the
affected members of consecutive generations, which can be
explained by anticipation [28]. However, the majority of those
studies are of limited value due to small sample size, lack ofgenetic conﬁrmation or no deﬁnitions of peripheral neuropathy.
A larger study by Hermans et al. [29] showed electrophysiologi-
cal abnormalities meeting criteria of peripheral neuropathy
in 16/93 patients (17%) with genetically conﬁrmed DM1 but the
course of neuropathy in these patients was subclinical.
2. Methods
We prospectively studied patients with genetically conﬁrmed
DM2 (n = 30) and DM1 (n = 32). Molecular evaluation for DM1
and DM2 included two-step analysis with standard polymer-
ase chain reaction (PCR) and repeat primed PCR (RP-PCR)
method applied for detection of long expansions, originally
developed as triplet primed PCR (TP-PCR) for the molecular
analysis of DM1 [30]. This diagnostic approach has been
recommended by the European Molecular Quality Network
(EMQN Best Practice Guidelines and Recommendations on
Myotonic Dystrophy type 1 and 2). All but one DM1 patients
carried expansions above 100 CTG repeats (detected by RP-
PCR) and a single case harbored 75 CTG within the range
ampliﬁable by standard PCR. In normal DM2 alleles, the
complex size ranges from 104 to 176 bp which is usually
reported in base pairs length due to highly polymorphic TG
and TCTG repeat tracts. In all 30 DM2 patients, the presence of
expansions was conﬁrmed by RP-PCR.
Patients were evaluated at the Department of Neurology,
Medical University of Warsaw. The DM2 group included
16 women (53.33%) and 14 men (46.67%) with the mean age
of 47.65  11.92 years (range 25–63), and the DM1 group
included 10 women (31.25%) and 22 men (68.75%) with the
mean age of 36.9  12.35 years (range 10–64). The mean
estimated disease duration was 11.92  8.83 years (range 2–31)
in the DM2 group and 9.42  7.68 years (range 1–49) in the DM1
group. The mean age at the time of overt clinical manifestation
was 36.27  13.54 years (range 12–60) and 27.52  14.09 years
(range 1–50), respectively. In the DM2 group, the most common
symptoms were muscle weakness (40%), muscle stiffness
(32.5%) and muscle pain (26.67%), while muscle weakness
(62.5%) and muscle stiffness (31.25%) were the most common
symptoms in the DM1 group. Two patients in the DM2 group
and 4 patients in the DM1 group had diabetes mellitus
(type 2 in ﬁve of these patients). Moreover, a history of
hypothyroidism was noted in four patients with DM2 and one
patient with DM1. Both concomitant diseases were well
controlled (with normal results of laboratory tests), patients
did not complain of symptoms characteristic for polyneuro-
pathy (PNP), and there were no signs of polyneuropathy on
neurological assessment. Other known causes of PNP (e.g.
renal insufﬁciency or vitamin B1, B6 and B12 deﬁciency as well
as a history of alcohol abuse or chemotherapy) were excluded.
All patients underwent detailed neurological examination
performed by an experienced neurologist from the Neuro-
muscular Unit of our Department. Muscle strength was
assessed using the Medical Research Council (MRC) scale.
The following muscles were tested: neck ﬂexors and extensors
(sternocleidomastoideus, trapezius) and 14 bilateral muscles
(deltoideus, biceps and triceps brachii, extensor carpi radialis,
ﬂexors digitorum, iliopsoas, quadriceps, rectus and biceps
femoris, semitendinosus, tibialis anterior, extensor digitorum
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calculated by adding results for the tested muscles (from
proximal and distal muscles, lower and upper extremities
separately) and dividing the sum by the number of muscles
tested. [Upper extremities proximal MRC compound score was
calculated by adding the MRC scores of bilateral shoulder
abductors, elbow ﬂexors and elbow extensors divided by the
number of muscles tested (n = 6) whereas upper extremities
distal MRC compound score was calculated by adding the MRC
scores of bilateral wrist extensors and digit ﬂexors divided by
the number of muscles tested (n = 4). Similarly in lower limbs:
lower extremities proximal MRC compound score was calcu-
lated by adding the MRC scores of bilateral hip ﬂexors, knee
ﬂexors and knee extensors divided by the number of muscles
tested (n = 10) and lower extremities distal MRC compound
score – by adding the MRC scores of bilateral ankle dorsiﬂexors
and ankle plantar ﬂexors divided by the number of muscles
tested (n = 8)].
Deep tendon reﬂexes were scored as exaggerated (3), normal
(2), diminished (1) or absent (0). Pinprick, touch, vibration as well
as joint position sense were evaluated. The clinical investiga-
tion also included a number of questions referring to the most
common symptoms of PNP. The study protocol was approved
by the Ethics Committee at the Medical University of Warsaw
(No. KB 180/2008). A written informed consent was obtained
from all patients before ENG examination.
2.1. Nerve conduction studies
Electrophysiological studies were performed using the Keypoint
EMG system (Medtronic Functional Diagnostics). Motor nerve
conduction studies (MNCS) were performed unilaterally with
supramaximal surface stimulation on the median, ulnar, and
peroneal nerves and recording from the abductor policis brevis,
abductor digiti minimi and extensor digitorum brevis, respec-
tively. The F wave, an index of stimulus conduction in the
proximal part of lower motor neuron (spinal roots and the
proximal region of the peripheral nerves), was measured from
the median, ulnar and peroneal nerves. Sensory nerve conduc-
tion studies (SNCS) were also performed unilaterally with
surface orthodromic stimulation on the median, ulnar and sural
nerves. Skin temperature was measured and maintained above
32 8C. All amplitude values were measured as negative peak. The
results were obtained by a neurologist experienced in EMG who
was blinded for other patient data. All nerve conduction
parameters were compared to the normal values adopted in
our EMG laboratory (matched for age, gender and height) and
considered abnormal if differed from the mean values by more
than two standard deviations (SD).
An electrophysiological diagnosis of PNP (modiﬁed from Oh
[31]) was established when:
1. conduction velocity and/or prolonged distal latency were
abnormal in at least two separate motor nerves and/or
2. amplitude of the sensory nerve action potential (SNAP)
and/or conduction velocity were abnormal in at least two
separate sensory nerves.
For the diagnosis of PNP, the amplitude of the compound
muscle action potential (CMAP) was not taken into accountbecause it can be independently affected by the myogenic
process.
Moreover, we excluded from the study the patients with
entrapment neuropathies, especially carpal tunnel syndrome,
conﬁrmed according to the American Association of Electro-
diagnostic Medicine (AAEM, 2002) (comparison of sensory
latency of median nerve across the wrist with ulnar sensory
conduction across the wrist in the same limb or deﬁnite
conduction block under carpal tunnel; if necessary compari-
son of the median nerve distal latency – second lumbrical to
the ulnar motor nerve distal latency – second interossei).
2.2. Statistical analysis
Statistical analysis included descriptive statistics (mean
values and SD or median values and ranges) and the Wilcoxon
test or the Fisher's exact test for comparisons of variables
between groups. A generalized linear model (GLM) taking into
account gender and age was used for comparisons between
the DM1 and DM2 groups. All analyses were performed using
the SAS software, version 9.3. P < 0.05 was considered
statistically signiﬁcant.
3. Results
The demographic proﬁle of the two studied groups differed
signiﬁcantly: patients in the DM2 group were about a decade
older than patients in the DM1 group (p < 0.001) and the
majority of them were female (53.33% in the DM2 group vs
31.25% in the DM1 group; p < 0.05).
Patients in the DM2 group had predominant proximal limb
weakness, while all DM1 patients had predominant distal limb
weakness. The demographic and clinical characteristics of the
two groups are shown in Table 1.
Based on responses to questions referring to the most
common symptoms of PNP, no patient from either study group
reported positive or negative sensory symptoms characteristic
for the diagnosis of PNP. Pinprick, touch, vibration as well as
joint position sense were normal in all patients. Tendon
reﬂexes were exaggerated in ﬁve patients, diminished in three
patients, and absent in two patients in the DM2 group. In the
DM1 group, they were diminished in 16 patients and absent in
6 patients.
Results of the electrophysiological studies (MNCS
and SNCS) are presented in Table S1 (see supplementary
materials).
When results obtained in DM2 and DM1 patients were
compared to the normal values adopted in our EMG laboratory
(matched for age, gender and height), nonsigniﬁcant trends
were noted for reduced amplitude, increased latency and
decreased CV in SNCS in the median nerve among patients
with DM2 (23.08% vs. 6.06%, 23.08% vs. 12.12%, and 11.54% vs.
0%, respectively, in DM2 compared to DM1). A decrease in
CMAP amplitude in the median nerve was signiﬁcantly more
often seen in patients with DM1 (p < 0.05, Fisher's exact test).
Taking into account more distal distribution of symptoms in
DM1, we cannot exclude that this parameter may be
independently affected by the myopathic process. A surprising
ﬁnding was decreased CV across the elbow in the ulnar nerve
Table 1 – Demographic and clinical characteristics of the DM1 (n = 32) and DM2 (n = 30) groups.
Characteristics DM1 (n = 32) DM2 (n = 30)
Gender (M/F)* 22/10 14/16
Age, years (mean  SD; range)** 36.9  12.35 (10–64) 47.65  11.92 (25–63)
Age at disease onset, years (mean  SD; range) 27.52  14.09 (1–50) 36.27  13.54 (12–60)
Disease duration, years (mean  SD; range) 9.42  7.68 (1–40) 11.92  8.83 (2–31)
UE proximal MRC compound score 4.52  0.68 (3–5) 4.57  0.50 (3–5)
UE distal MRC compound score 4.02  0.76 (2–5) 4.84  0.36 (4–5)
LE proximal MRC s compound core 4.63  0.61 (3–5) 4.27  0.63 (2–5)
LE distal MRC compound score 3.75  1.09 (1–5) 4.60  0.53 (3–5)
Abbreviations: DM1, myotonic dystrophy type 1; DM2, myotonic dystrophy type 2; SD, standard deviation; MRC, Medical Research Council; UE,
upper extremities; LE, lower extremities.
* p < 0.05, Fisher's exact test;
** p < 0.001, Wilcoxon test.
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among DM2 patients (p < 0.05, Fisher's exact test). A trend for
decreased CMAP amplitude in the peroneal nerve as well as
reduced CV in SNCS in the ulnar nerve was also observed in the
DM1 group (21.43% vs. 9.68% and 12.5% vs. 4.35%, respectively,
in DM1 compared to DM2).
Abnormal results of the electrophysiological studies were
found in 8/30 (26.67%) patients in the DM2 group. The most
frequent ﬁndings included decreased SNAP amplitude in the
median nerve (6/8 patients, 75.0%) and in the ulnar nerve (4/8
patients, 50.0%). Decreased sensory CV in the median nerve
and increased F-wave latency in the peroneal nerve (both in
2/8 patients; 25.0%) were also found. In 4/8 patients, we
observed only one abnormality in nerve conduction studies,
most commonly reduced SNAP amplitude in the ulnar or
median nerve. In the remaining 4 patients, PNP was diagnosed
according to the above mentioned electrophysiological crite-
ria. Thus, the estimated incidence of PNP (with subclinical
changes only) in our DM2 group was 13.33%. Only in one of
these patients with PNP, an abnormality of the thyroid glandTable 2 – Demographic and clinical characteristics of the DM1 
confirmed PNP.
Characteristics DM1 (n = 3
PNP present
(n = 4)
P
Gender (M/F) 4/0 1
Age, yrs (mean  SD; range) 37.01  11.27
(29–50)
3
(
Age at disease onset, yrs (mean  SD; range) 23.67  14.15
(15–40)
2
(
Disease duration, yrs (mean  SD; range) 13.33  3.51
(10–17)
9
(
UE proximal MRC compound score 4.58  0.46
(4–5)
4
(
UE distal MRC compound score 3.80  0.42
(3–4)
4
(
LE proximal MRC compound score 4.78  0.36
(4–5)
4
(
LE distal MRC compound score 3.83  1.12
(2–5)
3
(
Abbreviations: DM1, myotonic dystrophy type 1; DM2, myotonic dystrop
MRC, Medical Research Council; UE, upper extremities; LE, lower extremhad been diagnosed in the past, but normal thyroid function
was ascertained at the time of EMG examination. The
demographic and clinical characteristics of the DM2 patients
with or without conﬁrmed PNP are shown in Table 2.
Abnormal results of nerve conduction studies were
obtained in 9/32 (28.13%) patients in the DM1 group. The
most frequent ﬁndings included decreased SNAP amplitude
(5/9 patients, 55.56%) and decreased sensory CV (4/9 patients,
44.44%) in the ulnar nerve as well as increased F-wave latency
and decreased motor CV in the median nerve (both in
2/9 patients; 9.88%). We did not ﬁnd decreased motor CV
across the elbow in the ulnar nerve in any of the patients with
abnormal parameters of SNCS in this nerve. In 5/9 patients, we
observed only one abnormality in nerve conduction studies
(most often decreased CV in the ulnar or median nerve or
increased latency of the F-wave in the peroneal nerve). In the
other four patients, PNP was diagnosed according to the
above mentioned criteria, and thus the incidence of PNP in
DM1 (with subclinical changes only) can be estimated at
12.5%. Only one of these patients with PNP had a prior historyand DM2 patients with or without electrophysiologically
2) DM2 (n = 30)
NP absent
(n = 28)
PNP present
(n = 4)
PNP absent
(n = 26)
8/10 3/1 12/15
6.89  12.65
10–64)
50.25  13.15
(37–63)
47.18  11.95
(25–63)
7.93  14.28
1–50)
39.75  20.98 (15–60) 35.64  12.35 (12–60)
.01  7.93
1–40)
11.75  7.85
(3–22)
11.95  9.17
(2–31)
.51  0.71
3–5)
4.51  0.50
(4–5)
4.58  0.49
(4–5)
.04  0.79
3–5)
4.71  0.47
(4–5)
4.86  0.34
(4–5)
.62  0.63
3–5)
4.37  0.61
(3–5)
4.25  0.64
(2–5)
.74  1.09
1–5)
4.55  0.53
(3–5)
4.61  0.54
(3–5)
hy type 2; PNP, polyneuropathy; yrs, years; SD, standard deviation;
ities.
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clinical characteristics of the DM1 patients with or without
conﬁrmed PNP are shown in Table 2.
When results obtained in both groups were compared using
statistical generalized linear models that included age and
gender as confounding factors, a few signiﬁcant differences
were found: distal latency and F-wave latency in the median
nerve were longer in the DM2 group (p < 0.05 for both), and
distal latency in the peroneal nerve in was longer in the DM1
group (p < 0.05) but all mean values in both groups were within
normal limits. In addition, we found lower values of SNAP
amplitude in the median nerve in DM2 patients (p < 0.001) and
longer latency of SNAP in the sural nerve in DM1 patients
(p < 0.05), again with all mean values in both groups within
normal limits. We also noted a nonsigniﬁcant trend for longer
F-wave latency (but still within normal limits) in the peroneal
nerve in the DM2 group compared to the DM1 group.
4. Discussion
Our DM2 patients were signiﬁcantly older than patients in the
DM1 group. Similar age difference, albeit statistically nonsig-
niﬁcant, was reported by Logigian et al. [32]. This age difference
is sufﬁciently explained by a more severe disease course of
DM1 which makes patients seek help earlier and thus the
diagnosis is made at a younger age.
Normal results of nerve conduction studies in DM2 patients
have been usually reported in the literature [1,2,5,6]. In our
group, however, we found some abnormal results of
electrophysiological studies in nearly 27% of patients with
DM2. The most frequent ﬁndings included decreased SNAP
amplitude in the median and ulnar nerve. The electrodiag-
nostic criteria for entrapment neuropathies of the upper limb
were not fulﬁlled. On the other hand, we could diagnose PNP
according to the above mentioned electrophysiological criteria
in only 4 patients (13.33%) [31]. PNP was mostly of sensory and
axonal character and the changes were subclinical in the
majority of patients. Two patients in the DM2 group had
diabetes mellitus (type 1 in one of them) and a history of
hypothyroidism was noted in four patients but among the four
patients with PNP, abnormal thyroid function had been
diagnosed in the past only in one patient, and a euthyroid
state was ascertained at the time of the study. This suggests
that peripheral nerve dysfunction in our DM2 patients was
independent of other metabolic factors and is most likely
primary. Moreover, in another 4 patients we observed only one
abnormality in nerve conduction studies, which was not
sufﬁcient to diagnose PNP. The most common abnormalities
were reduced SNAP amplitudes in the ulnar and median nerve.
The authors have not encountered any description of
peripheral nerve involvement in genetically conﬁrmed DM2
in the literature. In most recently published reviews [2,6],
normal nerve conduction study results are considered a
feature of DM2. In a study by Dabby et al. [33], neuropathy
was found in 2 of 10 patients with genetically conﬁrmed DM2,
but the criteria for the diagnosis of PNP were not listed and the
patient sample was very small.
Some electrophysiological studies of DM1 suggest that the
incidence of PNP ranges from 18% [17] to 45% [14], and onaverage is 20–30% [13,15,16]. In a recent study of 93 patients
with DM1, Hermans et al. [29] found evidence of PNP in 17% of
patients using clearly deﬁned electrophysiological criteria. The
presence of PNP in DM1 was also conﬁrmed by pathological
studies showing involvement of sensory ﬁbers [25,34–36]. In
our study, we were able to diagnose PNP based on the
electrophysiological criteria mentioned in the Methods section
[31] in only 12.5% patients with DM1. Some other reports,
however, indicated no PNP in DM1 by showing normal or near
normal results of conduction studies [23–25]. These conﬂicting
results could be attributed to varying patient populations
(number of investigated patients, lack of genetic conﬁrmation),
different electrophysiological methods or speciﬁc protocols
used (e.g., type of electrodes or needles, number of limbs or
nerves tested, motor/sensory nerves only). In a histological
study on transgenic DM300 mice, no evidence of nerve ﬁber
involvement was found [26]. Some authors indicated that
conﬂicting results could result from different lengths of CTG
repeats in DM 1 patients. This notion may be supported by
studies performed in transgenic DMSXL mice carrying a larger
CTG expansion and expressing more severe DM 1 phenotype
than DM300 mice, with deﬁnite histologic and electrophysio-
logic features of peripheral neuropathy [27].
Polyneuropathy in DM1 is described in most cases as an
axonal sensory or sensorimotor neuropathy characterized by
decreased CV and/or reduced SNAP amplitudes [13–17,
20–22,29]. In our study, the most common abnormal
electrophysiological ﬁndings in patients with DM1 included
decreased SNAP amplitude and decreased CV in the ulnar
nerve as well as increased F-wave latency and decreased CV in
the median nerve which allowed us to categorize the PNP in
DM1 as a mostly sensory axonal neuropathy, similarly to the
DM2 group.
In most cases reported in the literature, PNP was revealed
by the electrophysiological examination, without patient
complains or marked symptoms in neurological examination,
suggesting its mild or even subclinical nature. Also in our
study, none of the patients with PNP complained of sensory
symptoms and neurological examination of sensation was
normal in all patients. Thus, PNP in these patients may be
considered subclinical, which is consistent with recently
published reports [18,29].
The presence of PNP did not correlate with patient age or
disease duration in any of the studied groups. Our ﬁndings are
consistent with some previously published reports [13,15,20,29],
although such an association was found in other studies
[14,18,21]. According to Logullo et al. [14] a more severe clinical
picture of DM1 was signiﬁcantly associated with the presence of
PNP but the degree of nerve conduction abnormalities did not
correlate with the severity of myopathy and clinical im-
pairment, thus suggesting independent muscle and nerve
involvement. The observation that PNP tends to progress
irrespective of the clinical severity of myopathy was also
conﬁrmed by other authors [15,18,20]. More recently, however,
Hermans et al. [29] found a correlation between peripheral
nervous system involvement, decreased muscle strength, and
absence of Achilles tendon reﬂexes.
Another unsettled issue regarding peripheral nervous
system involvement in DM1 is its primary or secondary nature.
Some authors supported the notion of primary peripheral nerve
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other metabolic factors [14,16,17,20,29,37]. Studies performed in
transgenic mice (DMSXL) also demonstrated the presence of
motor neuropathy. This neuropathy seemed to be independent
of abnormalities of the thyroid gland or the pancreas because
neuropathy did not develop in transgenic DM300 mice used to
generate DMSXL mice [26,27].
In our study, four patients in the DM1 group had diabetes
mellitus type 2 and a history of hypothyroidism was noted in
one patient, but diabetes was identiﬁed in only one of 4
patients with polyneuropathy and the condition was well
controlled. This observation may support the notion of
primary peripheral nerve dysfunction in DM1.
In ﬁve of nine DM1 patients with abnormal results of nerve
conduction studies, only one abnormality was observed which
was not enough to establish the diagnosis of PNP. The most
common abnormal ﬁndings were decreased CV along the
whole ulnar and median nerve (not only within entrapment
sites) as well as increased latency of the F-wave in the peroneal
nerve. Similar results were reported in a study by Bae et al. [17]
in which 8 of 18 patients had abnormal nerve conduction study
ﬁndings (most common were abnormal peroneal motor nerve
conduction and the H-reﬂex) but a sensorimotor axonal
polyneuropathy was diagnosed only in one patient. Bae
et al. [17] suggested that some minimal abnormalities found
in conduction studies (which did not allow the diagnosis of
PNP) could also be explained by technical factors (e.g., muscle
wasting) or concomitant conditions such as lumbosacral
polyradiculopathy.
The aim of our study was also to compare the nerve
conduction study results in DM1 and DM2 and a number of
signiﬁcant differences was found between these two groups.
Distal latency and F-wave latency in the median nerve were
longer in the DM2 group, while longer distal latency in the
peroneal nerve was seen in the DM1 group. In addition, SNCS
also revealed lower values of SNAP amplitude in the median
nerve in DM2 patients and longer latency of SNAP in the sural
nerve in DM1 patients. Of note, however, all mean values in
both studied groups were within normal limits. We also noted
a nonsigniﬁcant trend for longer F-wave latency (but still
within normal limits) in the peroneal nerve in the DM2 group
compared to the DM1 group.
We identiﬁed only one report in the literature that
compared DM1 and DM2 from the neurophysiological point
of view [32]. The aim of that study was to evaluate the severity,
type and distribution of myotonic discharges in both types of
myotonic dystrophy and the authors did not report nerve
conduction study results. Our results indicate that abnormali-
ties in nerve conduction studies in both types of myotonic
dystrophy occur at a similar rate (25–30%). Thus, examination
of the peripheral nerves seems not to be very useful when
differentiating between DM1 and DM2.
In our study, we quite frequently encountered electrophys-
iological evidence of some kind of peripheral nerve involve-
ment in both types of myotonic dystrophy. However, we were
able to diagnose PNP based on NCS in only 13.33% of patients
with DM2 and in 12.5% of patients with DM1. It is of interest
that none of our patients with PNP complained of sensory
symptoms and neurological examination of sensation was
normal in all patients. Thus, PNP in both types of myotonicdystrophy may be considered subclinical and categorized as
sensory axonal based on nerve conduction study results. We
also believe that the peripheral nervous system involvement is
unrelated to other metabolic or endocrine diseases such as
diabetes mellitus or hypothyroidism. This may support the
notion of primary peripheral nerve dysfunction in DM2 and
DM1.
In conclusion, this is the ﬁrst study to prove the presence of
peripheral nerve involvement in genetically conﬁrmed DM2,
although its degree may be minor, like in DM1. Peripheral
nerves are quite frequently involved in both types of myotonic
dystrophy (with a similar incidence of about 25–30%) but
abnormalities fulﬁlling the electrophysiological criteria of PNP
are rarely found (in about 13% of cases). As PNP in DM2 and
DM1 may be expected to be subclinical, other causes of
peripheral nerve involvement should be considered when
symptoms of a marked sensory or sensorimotor PNP are found
in the neurological or electrophysiological examination.
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